Do not merge label and higher-dose institutional dialysis protocols
The label includes CrCl exactly 30 in its >=30 band. UCSF prints >30 and <30, omitting exactly 30, and uses higher doses and different HD scheduling.
Before applying: Keep source-specific dose, interval, indication, weight basis and modality together. The official threshold is explicit; seek institutional clarification rather than silently changing its headings.
Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (9)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The labeled adult doses for cSSSI and S. aureus bacteremia differ from UCSF institutional high-dose regimens. Check infection, weight convention and dialysis modality.
Before applying: The labeled adult doses for cSSSI and S. aureus bacteremia differ from UCSF institutional high-dose regimens. Check infection, weight convention and dialysis modality.
Also check: Cubicin - product and source limitations
Official source
Daptomycin for injection - Fresenius Kabi USA 500 mg vial
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Renal measure
CrCl in mL/min; Cockcroft-Gault with actual body weight in the selected PK table
Source revision
5/2022
Retrieved
2026-09-10 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
The source explicitly includes exactly CrCl 30; do not silently repair a different institutional heading.
Selected named sections only; not a complete monograph or independent clinical approval.
Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.
Renal dosing, restrictions and evidence limits
The Fresenius Kabi label places CrCl exactly 30 mL/min in the at-least-30 category. Adult cSSSI uses 4 mg/kg every 24 hours and S. aureus bloodstream infection 6 mg/kg every 24 hours. Below 30, including HD/CAPD, the respective doses are every 48 hours, after HD when possible. Renal function and CPK require monitoring more often than once weekly in renal impairment. Pediatric renal regimens are unestablished. Reconstitution and storage differ among daptomycin formulations; this source does not establish interchangeability of preparation instructions.
Source revision: 5/2022 | Retrieved: 2026-09-10. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
Daptomycin for injection - Fresenius Kabi USA 500 mg vial
Source retrieved 2026-09-10 - confirm current applicability
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Before using this finding
Higher-dose institutional regimens and the missing exactly-30 heading require source-specific review, not dose/interval mixing.
Dialysis evidence: A regimen is reported in selected content
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Cubicin - UCSF Infectious Diseases Management Program
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
renal boundary and dialysis protocol difference
Do not merge label and higher-dose institutional dialysis protocols
The label includes CrCl exactly 30 in its >=30 band. UCSF prints >30 and <30, omitting exactly 30, and uses higher doses and different HD scheduling.
How to use this: Keep source-specific dose, interval, indication, weight basis and modality together. The official threshold is explicit; seek institutional clarification rather than silently changing its headings.
The labeled adult doses for cSSSI and S. aureus bacteremia differ from UCSF institutional high-dose regimens. Check infection, weight convention and dialysis modality.
How to use this: The labeled adult doses for cSSSI and S. aureus bacteremia differ from UCSF institutional high-dose regimens. Check infection, weight convention and dialysis modality.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Daptomycin for injection - Fresenius Kabi USA 500 mg vial
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Method: CrCl in mL/min; Cockcroft-Gault with actual body weight in the selected PK table
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/daptomycin/
Usual Dosing (Adults)
Complicated skin/skin structure infection: CUBICIN 4 mg/kg IV over 30 minutes in 0.9% sodium chloride every 24 hours for 7 to 14 days.
S. aureus bloodstream infection, including right-sided endocarditis due to MSSA or MRSA: 6 mg/kg IV over 30 minutes in 0.9% sodium chloride every 24 hours for a minimum of 2 to 6 weeks, with duration based on the working diagnosis. The source notes limited safety data beyond 28 days; in its cited phase 3 study, 14 patients received >28 days and 8 received >=6 weeks.
CPK elevation appeared more common with more-than-once-daily dosing in phase 1/2 trials, so do not dose more frequently than once daily.
Primarily eliminated by the kidneys. In renal impairment, check renal function and CPK more often than weekly. The source clearance method is Cockcroft-Gault using actual body weight.
DailyMed / Fresenius Kabi USA, LLC · Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Renal method: CrCl in mL/min; Cockcroft-Gault with actual body weight in the selected PK table Source date: 5/2022 Retrieved: 2026-09-10
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
The source explicitly includes exactly CrCl 30; do not silently repair a different institutional heading.
Dialysis evidence: A regimen is reported in selected content
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The Fresenius Kabi label places CrCl exactly 30 mL/min in the at-least-30 category. Adult cSSSI uses 4 mg/kg every 24 hours and S. aureus bloodstream infection 6 mg/kg every 24 hours. Below 30, including HD/CAPD, the respective doses are every 48 hours, after HD when possible. Renal function and CPK require monitoring more often than once weekly in renal impairment. Pediatric renal regimens are unestablished. Reconstitution and storage differ among daptomycin formulations; this source does not establish interchangeability of preparation instructions.
Selected named sections only; not a complete monograph or independent clinical approval.
Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.
Renal guidance: 2, renal dosing and 5, CPK monitoring
For adult CrCl <30 mL/min, use 4 mg/kg IV every 48 hours for complicated skin/skin-structure infection or 6 mg/kg every 48 hours for S. aureus bloodstream infection. The interval is every 24 hours at CrCl >=30. The 48-hour schedule includes HD and CAPD. On HD days, dose after dialysis when possible. Check renal function and CPK more often than weekly in renal impairment.
GlobalRPh-hosted RX List · Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Renal method: CrCl in mL/min; selected PK table specifies Cockcroft-Gault using actual body weight Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-10
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Keep the infection-specific dose, interval and dialysis schedule from the same source.
Dialysis evidence: A regimen is reported in selected content
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The CUBICIN RF mirror gives 4 mg/kg every 24 hours for adult complicated skin/skin-structure infection and 6 mg/kg every 24 hours for adult S. aureus bloodstream infection when CrCl is at least 30 mL/min. Below 30, including HD and CAPD, the respective doses are given every 48 hours; administer after HD when possible. Pediatric renal dosing is not established. In renal impairment, renal function and CPK need assessment more frequently than weekly. These indication-specific label regimens are not the UCSF higher-dose protocol.
Selected named sections only; not a complete monograph or independent clinical approval.
A label mirror is not independent corroboration of its underlying label. See the separately attributed official source; concordance is limited to selected sections.
GlobalRPh RX List / product-label mirror · Daptomycin (Cubicin), adult IV treatment of cSSSI or S. aureus bacteremia
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Adult regimen and renal adjustment
The displayed table uses 6 mg/kg IV daily for bacteremia, osteomyelitis and other severe infections, or 4 mg/kg daily for UTI/skin infection. At CrCl <30 mL/min it retains the selected dose but extends the interval to every 48 hours. HD follows the <30 interval, with administration after dialysis on treatment days.
daptomycin:unmc-daptomycin-1 · Source locator: Rendered PDF page 21: daptomycin row
Source-specific limits
This institutional source includes off-label indications. Its outpatient post-HD and higher-dose salvage options were not imported here. Parsed-text page numbers did not match the rendered PDF; this summary uses the displayed page, not the conflicting parsed locations.
UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: CrCl in mL/min where specified; no equation inferred. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
IV dosing at CrCl >30 mL/min is 8-10 mg/kg daily; below 30, 8-10 mg/kg every 48 hours. The webpage omits exactly 30. Certain VRE infections may require up to 12 mg/kg with ID pharmacy guidance.
IHD: 8-10 mg/kg initially and after HD; an unstable dialysis schedule may instead use every-48-hour dosing. CVVHD: 6-8 mg/kg daily. Flow above 2.5 L/hour can require higher dosing; obtain specialist input. This continuous regimen has not been evaluated for other modalities such as CVVH.
Weight is total body weight unless it exceeds 120% of ideal body weight, when UCSF uses adjusted weight. Daptomycin is not effective for pneumonia. These high-dose institutional recommendations remain distinct from label regimens.
UCSF Infectious Diseases Management Program · Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Renal method: Institutional CrCl headings; source-specific weight selection and CVVHD flow caveats Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-10
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Before using this finding
Higher-dose institutional regimens and the missing exactly-30 heading require source-specific review, not dose/interval mixing.
Dialysis evidence: A regimen is reported in selected content
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
UCSF prints CrCl >30 and <30 headings with 8-10 mg/kg IV every 24 and 48 hours, respectively; exactly 30 is absent from those headings. Its intermittent-HD schedule is 8-10 mg/kg once now and after HD, with every-48-hour dosing as an alternative when the HD schedule is unstable. CVVHD uses 6-8 mg/kg every 24 hours; flow above 2.5 L/hour may require more with ID/ASP input. Other continuous modalities, including CVVH, were not evaluated. UCSF uses total weight unless above 120% of ideal weight, then adjusted weight. Therapy is restricted and is not for pneumonia.
Renal method: Intermittent HD or CVVHD with specified flow and dosing weight. Source date: Online guidance checked 2026-11-07; section revision not established. Retrieved: 2026-11-07
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
For intermittent HD, UCSF uses 8-10 mg/kg IV initially and after HD, with every-48-hour dosing as an alternative for an unstable dialysis schedule. For CVVHD it lists 6-8 mg/kg IV every 24 hours; flow above 2.5 L/hour can require specialist-guided changes. Use total weight unless it exceeds 120% of ideal, when UCSF uses adjusted weight. Other CRRT modes were not evaluated.
RDM73-cubicin-professional-1 · Source locator: Dosing weights and hemodialysis
Additional summaries stored on this page: 2 official-label, 2 RX List, 4 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.
